Malignant Fibrous Histiocytoma of Bone and Osteosarcoma — Treatment & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Osteosarcoma is the most common primary malignant bone tumour, characterised by the production of osteoid (immature bone matrix) by malignant mesenchymal cells, most frequently arising in the metaphysis of long bones — particularly the distal femur, proximal tibia, and proximal humerus — in adolescents and young adults during skeletal growth. Malignant fibrous histiocytoma of bone (MFH-bone) — now reclassified in the 2020 WHO Classification of Bone and Soft Tissue Tumours as undifferentiated high-grade pleomorphic sarcoma of bone — is a high-grade spindle cell malignancy of bone without specific differentiation, histologically and clinically similar to osteosarcoma. Both tumours present most commonly in the second decade of life, with a secondary peak in adults over 60 years (often secondary to Paget's disease or radiation). Incidence is approximately 3–4 per million population annually. Treatment is multimodal: neoadjuvant chemotherapy (before surgery) to shrink the tumour and assess chemosensitivity, followed by wide surgical resection with limb-salvage reconstruction (or amputation when necessary), then adjuvant chemotherapy. This multimodal approach is delivered by specialist orthopaedic oncology teams at sarcoma centres.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

Wide surgical resection is the definitive local treatment for all patients with resectable osteosarcoma or MFH of bone following neoadjuvant chemotherapy, performed by orthopaedic oncology surgeons at specialist sarcoma centres. Surgery is indicated for: localised osteosarcoma or MFH-bone following 2–3 cycles of neoadjuvant chemotherapy (MAP — methotrexate, doxorubicin, cisplatin; or AP — doxorubicin, cisplatin) achieving resectability; and selected patients with oligo-metastatic disease where complete resection of both primary and metastatic sites may be achieved. Diagnosis is established by core needle biopsy (performed at the treating sarcoma centre to ensure correct biopsy tract planning for subsequent resection) interpreted by an expert bone pathology team; immunohistochemistry (Satb2 staining for osteosarcoma, MDM2 amplification to exclude low-grade osteosarcoma subtypes), MRI of the affected bone and joint, and CT chest (pulmonary metastasis staging) are required before treatment planning. Wide surgical margins (>1 cm of normal tissue surrounding the tumour) are the primary predictor of local recurrence. Amputation is required when the neurovascular bundle is encased by tumour precluding limb salvage, or in recurrent disease after prior limb-salvage failure.

Surgical resection of osteosarcoma is a major procedure performed by an orthopaedic oncology surgeon, typically requiring 4–8 hours under general anaesthesia. Following neoadjuvant chemotherapy, the resection is planned using post-treatment MRI and CT to confirm surgical margins. The tumour and the entire compartment (including the biopsy tract) are excised en bloc with the planned wide margins. For distal femoral osteosarcoma — the most common site — a modular endoprosthetic reconstruction (tumour prosthesis) replaces the resected segment with a cemented metal implant articulating with the tibial tray of a knee replacement. For proximal tibial tumours, a gastrocnemius muscle flap covers the prosthesis. Allograft-prosthesis composite, intercalary allograft (for diaphyseal lesions), and rotationplasty (Van Nes procedure, where the ankle joint functions as a knee after tibial rotation) are alternative reconstruction strategies depending on patient age, growth plate status, and tumour extent. Paediatric patients with open growth plates may receive expandable prostheses to accommodate longitudinal bone growth. Limb-salvage surgery is associated with equivalent survival to amputation in most series, with a local recurrence rate of 5–10% at 10 years when wide margins are achieved.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

The introduction of multimodal treatment combining neoadjuvant chemotherapy and wide surgical resection has transformed outcomes for bone sarcoma over the past four decades. Five-year overall survival for localised osteosarcoma now exceeds 70% (compared to 10–20% with surgery alone in the pre-chemotherapy era). Chemotherapy histological response — assessed by the percentage of tumour necrosis in the resected specimen — is a key prognostic marker: good responders (>90% tumour necrosis, Huvos grade III–IV) have 5-year survival rates of 75–85%, while poor responders (<90% necrosis) have rates of 45–55%. Limb-salvage surgery achieves equivalent oncological outcomes to amputation when adequate surgical margins are obtained, while preserving functional limb use, mobility, and quality of life. Patient-reported outcome measures (TESS, MSTS score) demonstrate good-to-excellent limb function in 75–85% of patients after modular endoprosthetic reconstruction at 5 years. Novel therapeutic strategies including aerosol inhalation of interleukin-2, muramyl tripeptide (mifamurtide — approved in Europe as part of MAP chemotherapy for non-metastatic osteosarcoma), and emerging immunotherapy approaches continue to be evaluated in clinical trials.

Surgical complications of major limb-salvage resection and reconstruction include: wound healing problems and deep surgical site infection (5–15% — serious given the presence of a metallic implant, often requiring debridement, irrigation, and prolonged antibiotic suppression); local recurrence from inadequate surgical margins (10–15% at 10 years); endoprosthetic mechanical failure (aseptic loosening, periprosthetic fracture, bearing wear — cumulative 20–40% requiring revision surgery at 10 years); and vascular or nerve injury during resection. Chemotherapy-related toxicities for MAP or AP regimens include: severe nausea, vomiting, and mucositis; nephrotoxicity from cisplatin (requiring aggressive IV hydration, GCSF support, audiometry monitoring for cisplatin ototoxicity); cardiotoxicity from doxorubicin (cardiomyopathy — baseline and post-treatment echocardiography mandatory); bone marrow suppression requiring GCSF support; and alopecia. Methotrexate infusions require leucovorin (folinic acid) rescue and serial methotrexate level monitoring with renal function tests. Late effects of treatment including secondary malignancies (therapy-related AML from etoposide; radiation-induced sarcoma from radiotherapy), infertility from alkylating agents or radiotherapy, and radiation effects on growth plates in paediatric patients are important considerations in long-term survivorship care.

Hospital stay following major limb-salvage surgery is 7–14 days. Weight-bearing status and rehabilitation depend on the reconstruction type: endoprosthetic replacement typically allows protected weight-bearing from day 1–3; allograft reconstructions require non-weight-bearing for 3–6 months until bone healing. A physiotherapist begins quadriceps strengthening and range-of-motion exercises from day 1. Adjuvant chemotherapy (MAP or AP, 3–6 further cycles) resumes 3–4 weeks post-surgery once wound healing is confirmed, continuing for a total of 18–30 weeks from initial diagnosis. Outpatient physiotherapy continues for 6–12 months. Return to school or light work is possible at 3–6 months; sports and strenuous physical activities at 12–18 months after surgery when prosthetic rehabilitation is complete. Follow-up surveillance (clinical, CT chest, MRI of the primary site) occurs every 3 months for the first 2 years, every 6 months for years 3–5, then annually — matching the period of highest relapse risk. Psychological support addressing the diagnosis, body image change, and functional adaptation is an essential component of specialist sarcoma multidisciplinary care.